

like to clear up. The wolf is neither vicious nor huggable, dangerous nor lovable. It is merely one more interesting species long persecuted by humans throughout the centuries that requires a place to survive. It is true that a number of "Dr. Noitalls" have chosen the wolf to idolize, but most wolf biologists believe such idolatry is not in the long-term best interests of the species.

Koshland uses Alaska as the hypothetical state into which wolves might be reintroduced. Ironically, Alaska is the only state whose wolves are *not* on the Federal List of Endangered or Threatened Species. No reintroductions of wolves into Alaska are planned or necessary, and the state has even offered to supply wolves for reintroductions elsewhere. A more accurate example would have been Yellowstone National Park, where wolves were exterminated in the late 1920s and where the majority of the U.S. public favors reestablishment.

**L. David Mech**  
Chair, Wolf Specialist Group,  
World Conservation Union,  
c/o North Central Forest  
Experiment Station,  
U.S. Fish and Wildlife Service,  
1992 Folwell Avenue,  
St. Paul, MN 55108

## Health Care and Life Expectancy

The observations in Daniel E. Koshland Jr.'s editorial concerning hampering basic research (8 Oct., p. 159) apply equally to the creative pharmaceutical industry. President Clinton's supposed reduction of the cost of medical care reduces a negligible part of the cost at the cost of life expectancy. The increase in life expectancy the last 50 years has been attributable to new medicines. Basic research in the pharmaceutical industry will be hampered by price reductions. The industry will be forced to reduce basic long-range research and, therefore, better medicines for our grandchildren are unlikely to be discovered.

**George H. Hitchings**  
Burroughs Wellcome Co.,  
Post Office Box 12700,  
Research Triangle Park, NC 27709-2700

## Corrections and Clarifications

The four pictures of the moon accompanying the review by Ursula B. Marvin of *To a Rocky Moon: A Geologist's History of Lunar Exploration* by Don E. Wilhelms (9 July, p. 231) should have been in reverse order on the page.

# PFANSTIEHL

**We've added something new:  
Thioglycosides.**

Thioglycosides are a convenient source of the glycosyl donors needed for complex carbohydrate synthesis. They are highly crystalline and stable to a wide range of blocking/deblocking conditions. Thioglycosides can easily be converted to glycosyl halides for use under Koenigs-Knorr conditions or activated directly with a variety of reagents. Stereochemical control of the newly-formed glycosidic bond can be achieved by the appropriate group on C-2. Data sheet available.

## PFANSTIEHL LABORATORIES, INC.

*The source for carbohydrate chemistry*

1219 Glen Rock Avenue/Waukegan, IL 60085-0439  
Tel.: 1-708/623-0370/Toll Free: 1-800/383-0126  
FAX: 708/623-9173  
68-W



# MAKING THINGS WORK

Circle No. 17 on Readers' Service Card



## ONE-STOP SHOPPING FOR NON-ISOTOPIC DESIGNER LABELS.

**Fluorescein, biotin, alkaline phosphatase, digoxigenin\*, ABI dyes and ABI primer kits (M13, T7, T3, SP6.) Genosys offers a complete selection of custom-labelled oligos for PCR, DNA sequencing, gene mapping and chemiluminescent detection. We'll attach the label to your primer or probe, purify it, and deliver exactly what you need, on time and research-ready.**

**In North America, call  
(800) 2345-DNA**

# GENOSYS

**Genosys Biotechnologies, Inc.** The Woodlands, TX 77381-4241  
Phone: (713) 363-3693 Fax: (713) 363-2212  
**In U.K., France, Germany & Eire:** Genosys Biotechnologies, Inc.  
Phone: (+44) 223 425622 Fax: (+44) 223 425966  
**In Other W. European Countries:** MedProbe A.S. (Oslo, Norway)  
Phone: (+47) 2 20 01 37 Fax: (+47) 2 20 01 89  
**In Japan:** Kurabo Industries Ltd., Biomedical Dept. (Osaka, Japan)  
Phone: 0720-20-4504 Fax: 0720-21-9641

\* Chemistry licensed from Boehringer-Mannheim  
The PCR process is covered by patents owned by Hoffman-La Roche Inc.

Circle No. 4 on Readers' Service Card